Oral phosphate binders for the management of serum phosphate levels in dialysis patients

Ismail Mohammed, Alastair J. Hutchison

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Hyperphosphataemia is an inevitable consequence of end stage chronic kidney disease and is present in the majority of dialysis patients. Hyperphosphataemia is statistically associated with increased cardiovascular mortality among dialysis patients. Dietary restriction of phosphate and current dialysis modalities are not sufficiently effective to maintain serum phosphate levels within the recommended range so that the majority of dialysis patients require oral phosphate binders. However, benefits of achieving the recommended range have yet to be demonstrated prospectively. Unfortunately, conventional phosphate binders are not reliably effective and are associated with a range of limitations and side effects. Aluminium containing agents are highly efficient but no longer widely used because of well-established and proven toxicity. Calcium-based salts are inexpensive, effective and most widely used but there is now concern about their association with hypercalcaemia and vascular calcification. Sevelamer hydrochloride and lanthanum carbonate are non-aluminium, calcium-free phosphate binders. They are effective and reasonably well tolerated, but still do not control phosphate levels in all patients. Patient education programmes have been shown to be a useful and effective method of improving achievement of serum phosphate targets. © 2009 European Dialysis and Transplant Nurses Association/European Renal Care Association.
    Original languageEnglish
    Pages (from-to)65-70
    Number of pages5
    JournalJournal of Renal Care
    Volume35
    Issue number1
    DOIs
    Publication statusPublished - Mar 2009

    Keywords

    • Chronic kidney disease
    • Dialysis
    • Guidlines
    • Pharmaceuticals
    • Phosphate

    Fingerprint

    Dive into the research topics of 'Oral phosphate binders for the management of serum phosphate levels in dialysis patients'. Together they form a unique fingerprint.

    Cite this